Fragment / Modified GRF / Ipamorelin Blend is a research peptide formulation combining three well-studied synthetic peptides commonly examined in growth hormone and endocrine signaling research: Fragment (176–191), Modified GRF (1–29), and Ipamorelin. Fragment (176–191) is a modified C-terminal fragment of human growth hormone, while Modified GRF (1–29) is a stabilized analog of growth hormone–releasing hormone (GHRH). Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R) agonist. Together, this blend is formulated for laboratory research focused on growth hormone signaling, metabolic pathways, and coordinated endocrine response mechanisms.
Prior to the targeted synthesis and study of these peptides, research into growth hormone modulation and metabolic signaling relied largely on less specific hormonal interventions and generalized secretagogues. In controlled research settings, Fragment (176–191) has been studied for its role in lipid metabolism–related signaling pathways. Modified GRF (1–29) has been researched for its ability to stimulate endogenous growth hormone release via GHRH receptor activation while maintaining a short duration of activity. Ipamorelin has been examined for its selective receptor activity and minimal interaction with other pituitary hormones. The combination allows researchers to explore complementary mechanisms involved in growth hormone pulsatility, metabolic regulation, and endocrine coordination.
Currently, the Fragment / Modified GRF / Ipamorelin Blend is being investigated for potential applications in metabolic research models, endocrine pathway analysis, recovery-related signaling studies, and age-associated hormone regulation research. Additional investigation continues into its role in downstream anabolic and metabolic signaling processes, circadian hormone release patterns, and coordinated pituitary response mechanisms. Due to the complementary research interest of these peptides, this blend remains a compelling subject for ongoing laboratory investigation.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
The Fragment 176-191, Modified GRF (1-29), Ipamorelin Blend is designed for laboratory research examining metabolic signaling pathways, growth hormone axis communication, and endocrine marker behavior within controlled experimental environments. By combining a growth hormone fragment peptide with a GHRH analog and a GH secretagogue, this blend allows researchers to evaluate how metabolic signaling variables interact with upstream endocrine pathway activity.
Multi-peptide experimental protocols such as this are frequently used in research programs exploring the intersection of GH-axis signaling and metabolic biomarker responses. Because blended peptide research introduces additional variables, well-designed experimental frameworks typically emphasize strict endpoint definitions, controlled laboratory conditions, and consistent documentation practices to maintain reproducibility across study phases.
Fragment 176-191, Modified GRF (1-29), Ipamorelin Blend – Research Specifications:
| Format | Lyophilized peptide blend (research format) |
| Contents | Fragment 176-191 + Modified GRF (1-29) + Ipamorelin |
| Purity / Identity | Research-grade; refer to Certificate of Analysis (COA) for lot-specific analytical data |
| Source | Peptide synthesis with standardized processing and QC documentation |
| Appearance | Powder (lyophilized) |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture. Maintain lot integrity per laboratory SOPs. |
| Research Use Only | Supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
Fragment 176-191 is a modified segment of the human growth hormone sequence commonly referenced in research examining lipid metabolism and adipose tissue signaling. In laboratory models, investigators often evaluate this peptide fragment to study metabolic marker responses that may occur independently of broader GH-axis endocrine effects.
Modified GRF (1-29), sometimes referred to as a GHRH analog, is frequently studied in research environments exploring pulsatile growth hormone signaling patterns. The compound is designed to interact with the hypothalamic–pituitary axis, making it useful in experimental models that examine GH release dynamics and endocrine communication pathways.
Ipamorelin is a growth hormone secretagogue widely referenced in peptide research for its interaction with ghrelin receptor pathways and pituitary signaling mechanisms. In controlled laboratory experiments, this peptide is often included in protocols evaluating hormone signaling cascades and downstream metabolic marker responses.
When these peptides are combined within a research protocol, investigators can evaluate how metabolic signaling variables interact with GH-axis activation pathways. Some experimental designs examine whether multiple signaling inputs produce measurable differences in endocrine markers, metabolic indicators, or cellular signaling pathways compared to single-compound models.
Researchers studying the compounds individually can reference the individual product pages for Fragment 176-191, Modified GRF (1-29), and Ipamorelin.
Important Research Notice: Nordsci products are supported by lot-level analytical documentation. Certificates of Analysis are available to support internal audits, method alignment, and reproducibility across research studies.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
Fragment 176-191 is frequently studied in laboratory models investigating metabolic signaling pathways associated with lipid metabolism. When included within a peptide blend protocol, researchers may evaluate how metabolic markers respond alongside GH-axis signaling variables.
Modified GRF (1-29) and Ipamorelin are often used in GH-axis studies examining pulsatile hormone release patterns. In controlled research environments, investigators may monitor endocrine marker fluctuations across timed sampling intervals to understand signaling interactions.
Combining metabolic signaling peptides with GH-axis stimulators allows researchers to examine interactions between endocrine pathways and metabolic marker behavior. These studies may analyze downstream biomarker responses within multi-variable experimental systems.
Many peptide research programs include both blended and individual compound experimental conditions. This research design enables investigators to determine whether observed biomarker changes result from independent pathway activation or interactions between multiple signaling inputs.
The Fragment 176-191, Modified GRF (1-29), Ipamorelin Blend should be handled according to standard peptide laboratory procedures emphasizing contamination prevention, stable storage conditions, and detailed experimental documentation. Maintaining controlled research environments helps ensure reproducible experimental outcomes.
Protocol Design Considerations: Growth hormone and metabolic signaling experiments are sensitive to circadian rhythm timing, baseline metabolic phenotype, environmental conditions, and stress variables. Carefully controlled laboratory settings and standardized sampling windows are essential for reliable data interpretation.
Note: The information above is provided solely as a research reference summary. All experimental work must be conducted by qualified researchers in appropriate laboratory facilities.
Each lot of this peptide blend includes a Certificate of Analysis verifying peptide identity and quality parameters. These analytical reports support procurement verification, regulatory documentation, and reproducibility tracking across research programs.
Laboratories sourcing peptides for metabolic and endocrine signaling research typically prioritize traceable documentation, consistent synthesis standards, and reliable quality-control processes. Nordsci Peptides provides research-grade peptide materials supported by analytical documentation and manufacturing standards designed to support reproducible laboratory research.
IMPORTANT: This product is supplied exclusively for laboratory research use. It is not approved for human consumption or clinical application. Researchers are responsible for complying with all applicable regulatory and institutional guidelines.
